Download PDF
Hamostaseologie 2017; 37(01): 9-11
DOI: 10.1055/s-0037-1619830
Editorial
Schattauer GmbH

Progress in Haemostasis

From individual patients to pathophysiological insightsFortschritte in der HämostaseologieVon individuellen Patienten zu pathophysiologischen Einblicken
Johanna A. Kremer Hovinga
1   Department of Hematology & Central Hematology Laboratory, Inselspital, Bern University Hospital, Bern, Switzerland
2   Department of Clinical Research, University of Bern, Bern, Switzerland
,
Rüdiger E. Scharf
3   Division of Hemostasis, Hemotherapy & Transfusion Medicine, and Hemophilia Comprehensive Care Center, Heinrich Heine University Medical Center, Düsseldorf, Germany
4   Biological Medical Research Center, Heinrich Heine University, Düsseldorf, Germany
› Author Affiliations
Further Information

Publication History

received: 10 January 2017

accepted: 10 January 2017

Publication Date:
29 December 2017 (online)

Also available at
   Permissions and Reprints

 

 

  • References

  • 1 Scharf RE, Kemkes-Matthes B. Hämostaseologie – Progress in Haemostasis. GTH is moving to a European society. Hämostaseologie 2016; 36: 5-6.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Weibel ER, Palade GE. New cytoplasmic components in arterial endothelia. J Cell Biol 1964; 23: 101-112.
    CrossrefPubMedGoogle Scholar
  • 3 Mourik M, Eikenboom J. Lifecycle of Weibel-Palade bodies. Hämostaseologie 2017; 37: 15-26.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Byrnes JR, Wolberg AS. New findings on venous thrombogenesis. Hämostaseologie 2017; 37: 27-37.
    PubMedGoogle Scholar
  • 5 Kühne T. Diagnosis and management of immune thrombocytopenia in childhood. Hämostaseologie 2017; 37: 38-46.
    PubMedGoogle Scholar
  • 6 Haas SA, Dettmer V, Cathomen T. Therapeutic genome editing with engineered nucleases. Hämostaseologie 2017; 37: 47-54.
    PubMedGoogle Scholar
  • 7 Scharf RE. Alloantibodies to therapeutic FVIII and the use of emicizumab in hemophilia A. What and how can we do better? Hämostaseologie 2016; 36: 195-198.
    PubMedGoogle Scholar
  • 8 Berntorp E. Plasma-derived versus recombinant factor concentrates in PUPs: a never ending debate?. Hämostaseologie 2017; 37: 55-59.
    PubMedGoogle Scholar
  • 9 Brehm MA. Von Willebrand factor processing. Hämostaseologie 2017; 37: 61-74.
    PubMedGoogle Scholar